• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

HHS gives Vaxxas $22M to support vaccine patch tech

October 5, 2020 By Chris Newmarker

Vaxxas micropatch vaccine COVID-19
Vaxxas’ patch comes in a hockey-puck-shaped applicator with a foil seal. [Image courtesy of Vaxxas]
Vaxxas announced today that it has received a $22 million award from the Biomedical Advanced Research and Development Authority (BARDA) at U.S. HHS to support a clinical study involving the company’s vaccine-delivery patch.

The money will mostly pay for a Phase 1 clinical study in which Vaxxas’ high-density micro-array patch (HD-MAP) delivering pandemic influenza vaccine to more than 400 people. Researchers chose pandemic influenza vaccine for the $24.1 million study in order to comprehensively baseline the immune responses and safety of the novel HD-MAP vaccination platform.

Vaxxas (Cambridge, Mass.; Brisbane, Australia) is also actively investigating opportunities to improve the performance of other pandemic vaccines including against COVID-19, as well as a broad range of non-pandemic infectious disease vaccines.

Based on technology originally developed at the University of Queensland, Vaxxas’ HD-MAP includes a 9-by-9 mm array of thousands of very short projections around 250 microns in length. Invisible to the naked eye and coated with vaccine, the projections can quickly deliver vaccine to immune cells. Vaxxas officials claim the technology can deliver vaccine more efficiently than a needle and syringe.

“We are excited to partner with BARDA to rapidly deploy Vaxxas’ HD-MAP technology, which holds the promise of significantly improving pandemic response with needle-free vaccine delivery that is more effective and readily accepted,” Vaxxas CEO David L. Hoey said in a news release.

“Having validated our HD-MAP technology in clinical studies at commercial scale, we stand ready to be among the leading innovators who can solve critical challenges to global pandemic health crises, going beyond and enhancing the capabilities enabled by promising vaccines,” Hoey said.

Vaxxas collaborators include Merck (NYSE:MRK), the  World Health Organization and the Bill and Melinda Gates Foundation. German manufacturing equipment maker Harro Höfliger has agreed to help Vaxxas develop a high-throughput, aseptic manufacturing line.

 

Filed Under: Drug-Device Combinations, Featured, Funding Roundup Tagged With: BARDA, coronavirus, COVID-19, HHS, Merck, Vaxxas

IN CASE YOU MISSED IT

  • Another BD Alaris infusion pump recall is Class I
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
  • Horizon touts data from trials for thyroid eye disease infusion treatment
  • Genentech touts study results for spinal muscular atrophy drug in babies

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS